The hippocampus plays an important role in a number of normal physiological processes and in pathological conditions, including Alzheimer's disease and epilepsy. Development of a complete understanding of the molecular and cellular mechanisms of regulation of synaptic function in the hippocampus could lead to new Strategies for treatment of these disorders. Until recently, it was thought that most neuro- modulatory influences on hippocampal function required activation of extrinsic afferents and that all of the actions of glutamate, the major neurotransmitter intrinsic to the hippocampus, were mediated by activation of ligandgated cation channels. However, it is now clear that glutamate also activates receptors, known as metabotropic glutamate receptors (mGluRs), that are coupled to effector systems through GTP binding proteins. To date, 5 mGluR subtypes have been cloned. However, the precise roles of the different mGluR subtypes in regulating neuronal excitability and synaptic transmission in the hippocampus are not known. A complete understanding of both normal and pathological hippocampal function will require a detailed understanding of the roles of mGluRs in regulating hippocampal physiology. Interestingly, application of IS,3R- ACPD (a selective mGluR agonist) to hippocampal slices, potentiates cyclic AMP responses to agonists of other receptors that are positively coupled to adenylate cyclase. Also, IS,3R-ACPD has a number of important physiological effects in the hippocampus. These include, among others, a decrease in synaptic -inhibition in hippocampal area CA1 and a decrease in evoked population spikes in the dentate gyrus. However, the precise cellular and synaptic mechanisms by which mGluR agonists modulate inhibitory and excitatory synaptic responses in the hippocampus are not known. Furthermore, the physiological relevance of 1S,3R-ACPD-induced potentiation of cyclic AMP responses is not known. A series of experiments is proposed in which microelectrode and patch clamp recordings from hippocampal neurons will be used to test the hypothesis that 1S,3R-ACPD decreases synaptic inhibition in area CA1 and evoked population spikes in dentate gyrus by reducing excitatory transmission onto inhibitory interneurons and dentate granule cells, respectively. Also, experiments will be performed to determine the physiological role of mGluR-mediated potentiation of cyclic AMP responses in regulating synaptic transmission in the hippocampus. Finally, specific antibodies will be raised against each of the cloned mGluR subtypes. These will be used to determine the precise cellular and subcellular localization of the different mGluR subtypes in the hippocampal formation. These studies, coupled with the electrophysiological experiments, will provide valuable information regarding the roles of specific mGluR subtypes in regulating hippocampal function.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS031373-03
Application #
2269298
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1993-08-01
Project End
1996-07-31
Budget Start
1995-08-01
Budget End
1996-07-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Emory University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Stansley, Branden J; Conn, P Jeffrey (2018) The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. Curr Opin Pharmacol 38:31-36
Joffe, Max E; Centanni, Samuel W; Jaramillo, Anel A et al. (2018) Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies. ACS Chem Neurosci 9:2188-2204
Doria, Juliana G; de Souza, Jessica M; Silva, Flavia R et al. (2018) The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease. J Neurochem 147:222-239
Yohn, Samantha E; Conn, P Jeffrey (2018) Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia. Neuropharmacology 136:438-448
Gogliotti, Rocco G; Senter, Rebecca K; Fisher, Nicole M et al. (2017) mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Sci Transl Med 9:
Moehle, Mark S; Pancani, Tristano; Byun, Nellie et al. (2017) Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor. Neuron 96:1358-1372.e4
Walker, Adam G; Sheffler, Douglas J; Lewis, Andrew S et al. (2017) Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology 42:2553-2566
Gogliotti, Rocco G; Senter, Rebecca K; Rook, Jerri M et al. (2016) mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Hum Mol Genet 25:1990-2004
Niswender, Colleen M; Jones, Carrie K; Lin, Xin et al. (2016) Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. ACS Chem Neurosci 7:1201-11
Senter, Rebecca K; Ghoshal, Ayan; Walker, Adam G et al. (2016) The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Curr Neuropharmacol 14:455-73

Showing the most recent 10 out of 132 publications